MedTrace Logo

MK3207 for Treatment of Acute Migraines (3207-005)

NCT00712725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 676

Last updated 2015-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Conditions

Interventions

DRUG

MK3207- 2.5 mg

Arm 1: MK3207 2.5 mg taken after migraine onset.

DRUG

MK3207- 5 mg

Arm 2: MK3207 5 mg taken after migraine onset.

DRUG

MK3207- 10 mg

Arm 3: MK3207 10 mg taken after migraine onset.

DRUG

MK3207- 20 mg

Arm 4: MK3207 20 mg taken after migraine onset.

DRUG

MK3207- 50 mg

Arm 5: MK3207 50 mg taken after migraine onset.

DRUG

MK3207- 100 mg

Arm 6: MK3207 100 mg taken after migraine onset.

DRUG

Comparator: placebo (unspecified)

Placebo taken after migraine onset.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-01-31
Completion
2009-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712725 on ClinicalTrials.gov